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Abstract
The underlying genetic mechanisms and early pathological events of children with pri-
mary cardiomyopathy (CMP) are insufficiently characterized. In this study, we aimed to
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characterize the mutational spectrum of primary CMP in a large cohort of patients
≤18 years referred to a tertiary center. Eighty unrelated index patients with pediatric pri-
mary CMP underwent genetic testing with a panel-based next-generation sequencing
approach of 89 genes. At least one pathogenic or probably pathogenic variant was identi-
fied in 30/80 (38%) index patients. In all CMP subgroups, patients carried most frequently
variants of interest in sarcomere genes suggesting them as a major contributor in pediat-
ric primary CMP. In MYH7, MYBPC3, and TNNI3, we identified 18 pathogenic/probably
pathogenic variants (MYH7 n = 7,MYBPC3 n = 6, TNNI3 n = 5, including one homozygous
(TNNI3 c.24+2T>A) truncating variant. Protein and transcript level analysis on heart biop-
sies from individuals with homozygous mutation of TNNI3 revealed that the TNNI3 pro-
tein is absent and associated with upregulation of the fetal isoform TNNI1. The present
study further supports the clinical importance of sarcomeric mutation—not only in adult—
but also in pediatric primary CMP. TNNI3 is the third most important disease gene in this
cohort and complete loss of TNNI3 leads to severe pediatric CMP.
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1 | INTRODUCTION
!Primary cardiomyopathies (CMPs) are genetically heterogeneous
disorders with a large number of disease-causing genes. The growing
list of genes, reaching about 100 genes, and the overlap in genes
involved in different CMP subtypes cause significant challenges to
provide a genetic diagnosis for patients. CMP phenotypic subtypes
include hypertrophic (HCM), dilated (DCM), restrictive (RCM), left
ventricular non-compaction (LVNC), and arrhythmogenic right ven-
tricular (ARVC) CMP. In adults, sarcomeric genes represent the
major functional category, with the exception of ARVC, which is
dominated by mutation of desmosomal genes. There are only few
studies on current genetic testing in pediatric CMP. Depending on
the phenotypic composition of the cohorts, also including secondary
CMP, and different next-generation sequencing (NGS) strategies,
recent studies lead to the identification of pathogenic variants in
26% to 39% of pediatric patients.1,2 These genetic defects exhibit
variable expressivity and variable penetrance. Mutations in genes
encoding components of the sarcomere and related binding proteins,
Z-band, nuclear membrane, desmosomal, mitochondrial, and calcium
handling proteins have all been found in children with CMP.3 Only
now, NGS techniques and genetic variant interpretation guidelines
enable to unravel the genetic background in a reasonable percent-
age of primary CMP in children more systematically. We assembled
a cohort of pediatric primary CMP patients and present their clinical
phenotypes as well as spectrum of genetic variants. We present the
distribution of genetic variants in certain functional groups and high-
light genetic variants which can lead to severe CMP. In clinical prac-
tice, pediatric patients with mutation of Troponin I require special
attention.
2 | MATERIAL AND METHODS
2.1 | Clinical evaluation
Unrelated patients with CMP were recruited at the Charité – Uni-
versitätsmedizin Berlin and the German Heart Center Berlin, Berlin,
Germany between November 2011 and February 2017 (study design:
Figure S1). Written informed consent was obtained from each subject
or their legal guardians according to the Declaration of Helsinki.
The study was approved by the local institutional review board
(ID EA2/083/13, EA2/131/10, Charité – Universitätsmedizin Berlin).
Probands ≤18 years and available family members were evaluated by
medical history, physical examination, 12-lead electrocardiography,
and transthoracic echocardiography. For patients recruited after heart
transplantation (HTX), the clinical and echocardiographic data were
collected by retrospective review of patients' records. Patients with
a primary diagnosis of HCM, DCM, RCM, LVNC, or ARVC were
included in the study.4,5 Patients who had secondary CMP (syndromic,
neuromuscular, metabolic, or myocarditis) or CMP in combination
with a structural congenital heart defect were excluded. ARVC was
not included in the analysis of subgroups.
2.2 | Targeted NGS
NGS was carried out in genomic DNA samples isolated from
patient blood samples with the NucleoSpin Blood kit according to
the manufacturer's protocol (Macherey-Nagel, Germany). DNA
quantification occurred with a Qubit 3 fluorometer using appropri-
ate Qubit dsDNA reagents (Thermo Fisher Scientific, Invitrogen).
NGS was performed with a panel-based approach using the
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Illumina TruSight Cardio Sequencing Kit (Illumina).6 With this
approach, exonic regions of 174 cardiovascular disease genes spe-
cifically implicated in structural heart disease and arrhythmias were
sequenced (https://support.illumina.com/sequencing/sequencing_
kits/trusight-cardio-sequencing-kit.html). Library preparation and
enrichment was performed according to the manufacturer's proto-
col. Quantification of DNA libraries was performed with a Bio-
analyzer 2100 using the high sensitivity DNA kit or DNA 1000 kit
(Agilent Technologies). Patient DNA libraries were sequenced on a
NextSeq 500 platform with mid output cartridge v2 with paired
end sequencing (150 cycles) and dual indexing. Sanger sequencing
was applied to validate variants detected by NGS in index patients
and in family members for segregation analysis. Sanger sequencing
was performed according to standard laboratory protocols.7 The
primer for genomic amplification of cardiac troponin I (TNNI3)
polymerase chain reaction (PCR) products and Sanger sequencing
is available in Table S1.
2.3 | Alignment of raw data and variant calling
The libraries were demultiplexed using bcl2fastq v2.17.1.14. The
reads were then aligned using BWA-MEM v0.7.158 to the reference
GRCh37 (hs37d5.fa), separate read groups were assigned for all reads
from one lane, and duplicates were masked using Samblaster
v0.1.24.9 Standard quality control was performed using FastQC10 and
further quality control was performed by considering the minimal cov-
erage of all exons Illumina specifies as belonging to the target region
for the panel. The variants were then called using GATK
UnifiedGenotyper v3.7.11
2.4 | Bioinformatic evaluation and variant
classification
The called variants were evaluated with Variant Studio (Illumina)
for their minor allele frequency (<0.001) and mutation specifica-
tion. We used Genome Aggregation Database (gnomAD) as genetic
reference database for unaffected individuals (http://gnomad.
broadinstitute.org/).12 We evaluated 89 CMP disease genes that
have been ascertained in a series of patients, preferably including
family segregation data; CMP genes suggested from single case
reports were excluded (Table S2). Each detected variant was vali-
dated with databases displaying genetic variants for CMP: human
gene mutation database (HGMD, http://www.hgmd.cf.ac.uk/ac/
index.php) and atlas of cardiac genetic variation13 (ACGV, https://
cardiodb.org/ACGV/). Variants of interest (VOI) were classified as
pathogenic, probably pathogenic, or variant of uncertain signifi-
cance (VUS) according to the guidelines of the American College
of Medical Genetics and Genomics (ACMG)14 using the rec-
ommended frequency threshold in CMPs of <0.0001.15 For the
purpose of this study, variant classification was reconfirmed by the
classification on the National Center for Biotechnology (NCBI)
database, ClinVar.16 The most recent variant classification was
used in the final analysis (https://www.ncbi.nlm.nih.gov/clinvar/).17
For functional classification, the 89 genes evaluated in this study
were arranged into functional groups (Table S2).18
2.5 | Protein and mRNA expression analysis
Age-matched human ventricular biopsies obtained at time of cardiac
surgery (age range 5 months to 2.5 years) were subjected to protein
and total RNA isolation after liquid nitrogen treatment and mechanical
crashing. Powdered heart tissue was subjected to RNA isolation with
Trizol reagent (Invitrogen, Carlsbad, CA) and protein lysates were
obtained after incubation with RIPA buffer. Protein samples were ana-
lyzed by Western blot after sodium dodecylsulfate polyacrylamide gel
electrophoresis and transfer onto polyvinylidene difluoride membrane
(iBlot system; Invitrogen, Carlsbad, CA). For Western blot analysis,
membranes were incubated with the following primary antibodies:
anti-GAPDH (Life Technologies, AM4300), anti-HSC70/HSP70 (Enzo
Life Science, ADI-SPA-820), anti-TNNI1 (Sigma, HPA028190), anti-
TNNI3 (ThermoFisher, PA5-28964), anti-TNNT2 (ThermoFisher,
MA5-12960), and anti-MYBPC3 (R&D systems, AF7439). Quantifica-
tion of Western blots occurred with GelQuantNet (http://
biochemlabsolutions.com). Normalization of target protein levels
occurred with HSP70 expression.
For mRNA analysis, total RNA was isolated according to standard
protocols and transcribed into cDNA with SuperscriptII (Invitrogen).
Quantitative PCR (qPCR) was performed on a Taqman 7500 (Applied
Biosystems) using GAPDH as endogenous control. The relative mRNA
level was calculated according to the ΔΔCT method. The primers used
for qPCR are listed in Table S1.
3 | RESULTS
3.1 | Patient characteristics
During the study period, 80 individuals were recruited at our ter-
tiary center in the pediatric cardiology clinics (German Heart Center
and Charité – Universitätsmedizin Berlin, both in Berlin) with a diag-
nosis of primary CMP at age ≤ 18 years. The cohort of unrelated
Caucasian individuals (42 males and 38 females; mean age at diag-
nosis 4.8 years, range 1 day to 18 years) underwent genetic screen-
ing of 89 CMP-associated genes. The clinical characteristics of the
entire cohort are summarized in Table 1. Our pediatric CMP cohort
was composed of patients with DCM (n = 34), HCM (n = 23), LVNC
(n = 14), RCM (n = 7), and ARVC (n = 2) (Figure 1A). The age at
diagnosis was <10 years in 63 patients (79%) and <1 year in
34 patients (43%). Of note, the age of diagnosis did not affect the
relative CMP subtype frequency (Figure 1A-C). Family members of
61 index patients (77%) underwent clinical evaluation. In 27 of
these families, at least one additional affected family member was
identified resulting in a 44% positive yield of family screening (-
Table S3). The largest group was composed of DCM patients (43%)
of which 50% underwent HTX. In addition, the DCM group had the
highest rate of implanted ventricular assist device systems (47%),
extracorporeal membrane oxygenation systems (15%), and death
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(6%). Within the whole cohort, one-third of patients (n = 26; 33%)
already had a HTX at the time of enrollment or underwent HTX
during the study period (Figure 1D).
3.2 | Spectrum of detected rare variants in pediatric
primary CMP
To identify a potential genetic defect, we screened all index patients
with a panel-based NGS approach detecting genetic variants in
89 CMP-associated genes. In 46 of these 89 genes, we identified at
least one rare variant. In total, 126 detected variants were classified
as pathogenic (n = 17, 14%), probably pathogenic (n = 15, 12%), or
VUS (n = 94, 74%) (Table 2). Forty-two percentage (53/126) of all var-
iants were novel and not annotated in disease reference databases;
novel variants were mostly classified as VUS (42/53). One hundred
three Missense variants were found in >80% of cases (103/126) and
37 of them were novel (37/103). In addition, 9 indel/frameshift, 3 stop
gain, and 11 splice site rare variants were detected. From 75/126 rare
variants, for which inheritance was tested in the parents, 7 (10%)
arose de novo and 5/7 were classified as pathogenic and 2/7 were
probably pathogenic. A detailed summary of all VOI is supplied in
Table S4.
In 16 patients of our cohort, we could not detect any VOI
(16/80). More than one VOI was detected in 36 out of 80 patients
(1 VOI, n = 28; 2 VOI, n = 20; 3 VOI, n = 12; >3 VOI, n = 4). Each
individual carried 1.58 VOI on average. Pathogenic variants were
identified in 17 patients, probably pathogenic variants in 13 patients,
and VUS in 55 patients. At least one pathogenic or probably
TABLE 1 Clinical characteristics of the pediatric cohort at initial diagnosis
All (n = 80) DCM (n = 34) HCM (n = 23) LVNC (n = 14) RCM (n = 7) ARVC (n = 2)
Sex
Male, n (%) 42 (52.5) 11 (32.3) 18 (78.3) 7 (50) 4 (57.1) 2 (100)
Female, n (%) 38 (47.5) 23 (67.7) 5 (21.7) 7 (50) 3 (42.9) 0 (0)
Age at enrollment, mean in years 8.3 7.5 9.9 8.0 6.9 n.a.
Age at diagnosis, mean in years (IQR) 4.8 (8.8) 3.2 (4.7) 7.2 (12.1) 3.9 (7.8) 4.4 (3.0) n.a.
Family screening performed, n (%) 61 (76.3) 23 (67.7) 19 (82.6) 12 (85.7) 5 (71.4) n.a.
Positive result of family screening, n (%) 27 (33.8) 8 (23.5) 12 (52.2) 5 (35.7) 1 (14.3) n.a.
IVSd, mean in mm (SD) 9.1 (±7.6) 5.5 (±1.8) 16.7 (±9.6) 5.5 (±1.3) 5.0 (±1.3) n.a.
IVSd, mean z-score (SD) 3.6 (±6.8) 0.4 (±1.6) 10.6 (±8.4) 0.4 (±0.6) 0.2 (±0.8) n.a.
LVEDD (m-mode), mean in mm (SD) 39.4 (±13.0) 46.2 (±13.7) 33.8 (±11.1) 38.6 (±7.1) 26.0 (±4.4) n.a.
LVEDD, mean z-score (SD) 2.8 (±5.1) 7.0 (±4.2) −1.4 (±2.8) 2.5 (±3.0) −2.0 (±0.7) n.a.
LV-EF (auto 4CH monoplan), mean in % (SD) 46.5 (±22.4) 29.7 (±15.4) 66.8 (±14.7) 44.0 (±19.5) 62.1 (±12.6) n.a.
FS, mean in % (SD) 27.6 (±16.8) 15.1 (±6.7) 44.7 (±16.5) 26.2 (±11.5) 31.5 (±11.6) n.a.
AICD, n (%) 8 (10) 1 (2.9) 7 (30.4) 0 (0) 0 (0) n.a.
VAD, n (%) 22 (27.5) 16 (47.1) 1 (4.4) 2 (14.3) 3 (42.9) n.a.
ECMO, n (%) 6 (7.5) 5 (14.7) 0 (0) 0 (0) 1 (14.3) n.a.
HTX at enrollment, n (%) 17 (21.3) 13 (38.2) 0 (0) 3 (21.4) 1 (14.3) n.a.
HTX during study, n (%) 9 (11.3) 4 (11.8) 1 (4.4) 0 (0) 4 (57.1) n.a.
Deceased during study, n (%) 5 (6.3) 2 (5.9) 1 (4.4) 0 (0) 2 (28.6) n.a.
Abbreviations: AICD, automatic implantable cardioverter defibrillator; ARVC, arrhythmogenic right ventricular; DCM, dilated cardiomyopathy; ECMO,
extracorporeal membrane oxygenation; FS, fractional shortening; HCM, hypertrophic cardiomyopathy; HTX, heart transplantation; IQR, interquartile range;
IVSd, interventricular septum thickness at end-diastole; LV-EF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter (z-score,
normal reference range between -2 standard deviation [SD] and +2 SD); LVNC, left ventricular non-compaction; n.a., not applicable; RCM, restrictive
cardiomyopathy; VAD, long-term ventricular assist device.
F IGURE 1 CMP phenotypes in the overall cohort of pediatric
patients. A, Evaluation of the complete cohort of 80 pediatric patients
with CMP according to clinical subtypes. B, CMP subtypes <1 year of
age (age of diagnosis). C, CMP subtypes <10 years of age (age of
diagnosis). D, CMP subtypes of patients that underwent HTX. CMP,
cardiomyopathy; HTX, heart transplantation [Colour figure can be
viewed at wileyonlinelibrary.com]
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pathogenic variant was identified in 30/80 (38%) index patients.
Twenty-one patients (26%) with and 34 patients (43%) without a
pathogenic/probably pathogenic variant had at least one additional
VUS. None of the patients carried two different pathogenic variants.
Two patients had a complex genotype with two probably patho-
genic variants (Table S5).
3.3 | Rare variants indicate specific molecular
functional groups and complex genotypes
VOI were most frequently detected in genes encoding for myosin
heavy chain 7 (MYH7), cardiac myosin binding protein C (MYBPC3),
TNNI3, desmoplakin (DSP), LIM domain binding 3 (LDB3), and
myopalladin (MYPN) (Figure 2A). The VOI frequency per patient
was highest for MYH7 (16%) and MYBPC3 (9%). For all CMP sub-
groups, except for RCM, MYH7 yielded the highest number of
patients with a VOI per CMP gene (Figure 2B-E). Of note, the spe-
cific VOI distribution per gene was distinct for each CMP
subgroup.
Of the 80 patients, 39 had a VOI in a sarcomere gene
(13 MYH7, 7 MYBPC3, 6 TNNI3, 4 troponin T2 cardiac type
[TNNT2], 4 titin [TTN]), 16 in a desmosomal gene (6 DSP,
4 plakophilin 2 [PKP2], 3 desmocollin 2 [(DSC2], 3 desmoglein
2 [DSG2]), 15 in a z-disc gene (5 LDB3, 5 MYPN, 4 nexilin [NEXN]),
and 9 in a gene involved in transcription/splicing (4 PR domain-
containing protein 16 [PRDM16]) (Figure S2A). The functional
group “sarcomere” showed the highest frequency of genotype pos-
itive patients in all CMP subgroups (Figure S2B-E). Interestingly,
each CMP subgroup shows overrepresentation of distinct func-
tional groups: protein quality control for DCM, dystrophin complex
for HCM, mitochondria and nuclear envelope for LVNC, and tran-
scription/splicing for RCM. Variants in desmosome genes are
rarely detected in HCM patients. In children <1 year (n = 34), the
relative VOI frequency for the functional groups sarcomere, des-
mosome, z-disc, and transcription/splicing was similar compared to
the total cohort (n = 80) (Figure S2F). Note, functional groups com-
prising a large number of genes and/or exons are overrepresented
in this illustration.
3.3.1 | TTN variants
VOI inducing truncations of the TTN protein (n = 4, 3% of all VOI)
were rarely found and occurred in three RCM as well as in one DCM
patient, two probably pathogenic, and two VUS (Table S5). In RCM
patients, three TTN splice-site variants were identified in three indi-
viduals, respectively, two VUS and one probably pathogenic
(Figure 2E).
3.3.2 | Homozygous/compound heterozygous VOI
The vast majority of detected VOI were heterozygous, nevertheless;
we observed two homozygous (NEXN, TNNI3), and two compound
heterozygous (DSC2, MYBPC3) VOI. In one case, we identified com-
pound heterozygous mutation of MYBPC3 p.S858R with complete
deletion of the MYBPC3 gene on the second allele.19
TABLE 2 Genetic variants of 80 index patients with pediatric cardiomyopathy
Pathogenica Probably pathogenica Uncertain significancea Total
Variants according to phenotype, n 17 (14%) 15 (12%) 94 (74%) 126 (100%)
DCM 4 4 44 52
HCM 11 2 26 39
LVNC 1 4 13 18
RCM 1 2 10 13
ARVC 0 3 1 4
Category of variants, n
De novo 5 2 0 7
Not de novo (inherited) 4 9 55 68
Novelb 2 9 42 53
Not novel (known)c 15 6 52 73
Missense 11 9 83 103
Indel/frameshift 2 4 3 9
Stop gain 1 1 1 3
Splice site 3 1 7 11
Abbreviations: ARVC, arrhythmogenic right ventricular; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left ventricular non-
compaction; RCM, restrictive cardiomyopathy.
aClassification according to Richards et al14 Genetics in Medicine 2015.
bNovel indicates variants that have not been annotated in genetic disease reference databases ClinVar, ACGV, and HGMD.
cNot novel indicates variants that are annotated in genetic disease reference databases ClinVar, ACGV, and HGMD.
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3.3.3 | Hemizygous VOIs
Four hemizygous dystrophin (DMD), 1 four and a half LIM domains
1 (FHL1), and two tafazzin (TAZ) variants (Table S5) were also
observed.
3.3.4 | VOI in HTX
Within this pediatric CMP cohort, one-third of patients (n = 26),
mainly DCM and RCM, underwent HTX (Figure 1D). HTX patients
most frequently carried variants in DSP (4 VUS), DMD (3 VUS),
PRDM16 (3 VUS), and TTN (2 probably pathogenic, 1 VUS). Of note,
three TTN splice or truncating variants were found in RCM as well as
in DCM patients with HTX (Table S4). Fourteen HTX CMP patients
exhibited ≥2 VOI, six patients had one VOI, and no VOI was identified
in six patients.
3.4 | Homozygous loss of TNNI3 protein is
compensated by upregulation of fetal TNNI1
Within the pediatric CMP cohort, VOI were most frequently
detected in MYH7, MYBPC3, TNNI3, and DSP (Figure 2A). From this
group of VOI, 18 pathogenic/probably pathogenic variants in sarco-
mere genes (MYH7 n = 7, MYBPC3 n = 6, TNNI3 n = 5, DSP n = 0)
were identified, including one homozygous (TNNI3 c.24+2T>A) and
one heterozygous TNNI3 truncating variant (TNNI3 c.624dupT, p.
Glu209*). To further explore the impact of the five pathogenic/
probably pathogenic detected TNNI3 variants and another unrelated
homozygous truncating TNNI3 variant (c.240delG, p.Arg69Alafs*8),
we assessed the associated families (family 1-6) for their cardiac
phenotype and genotype (Figure 3A-F, Figure S3A-F and Table S6).
Patients 1-II:1 and 2-II:3 (Figure S4) are affected by DCM and
LVNC, respectively. Both patients were born to consanguineous
F IGURE 2 Distribution of variants in CMP genes. A, Number of VOI detected per gene, including pathogenic, probably pathogenic, and
VUS. B, Number of DCM patients with VOI per gene. C, Number of HCM patients with VOI per gene. D, Number of LVNC patients with VOI per
gene. E, Number of RCM patients with VOI per gene. Of note, TTN missense variants were not included. One patient may have several variants in
one gene. VOI were considered for each patient. CMP, cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy;
LVNC, left ventricular non-compaction; RCM, restrictive cardiomyopathy; VOI, variants of interest; VUS, variant of uncertain significance [Colour
figure can be viewed at wileyonlinelibrary.com]
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parents and carry homozygous TNNI3 variants that induce prema-
ture stop of protein translation. The splice site variant of 2-II:3
affects the donor splice site consensus sequence of intron_2-3 and
results in the truncated TNNI3 protein p.Ala8_Ala9insGluA-
rgAlaAlaGly* (Figure S5A-C).
The TNNI3 protein is composed of a cardiac specific region,
the IT arm region, and the flexible C-terminal tail (Figure 4A).20
All heterozygous TNNI3 missense variants detected in this
study cluster in exon 8 (Figure 4B). To further explore the mol-
ecular consequences of the truncating TNNI3 variants (c.240delG,
p.Arg69Alafs*8; c.24+2T>A; c.624dupT, p.Glu209*), we deter-
mined mRNA and protein levels in heart biopsies. The TNNI3
protein is absent in patients 1-II:1 and 2-II:3 (Figure 4C,D). Of
note, the protein level of TNNI1, the fetal TNNI variant, is mark-
edly higher in patients 1-II:1 and 2-II:3. The TNNI3 mRNA level
is markedly reduced in patient 1-II:1, suggesting degradation by
non-sense mediated decay, or not different from controls in
patient 2-II:3 (Figure 4E). Levels of the sarcomeric proteins TNNT2
and MYBPC3 were not significantly affected. The TNNI3 protein
level in a heart biopsy of patient 3-II:1 (p.E209*) was normal
(Figure S6A-C). In contrast, the TNNI3 and TNNI1 transcript levels
were higher in heart tissue of patient 3-II:1.
4 | DISCUSSION
In this study, we report the genetic basis of a cohort of 80 pediat-
ric patients with pediatric primary CMP referred to a tertiary cen-
ter. VOI were most frequently detected in the MYH7, MYBPC3,
TNNI3, and DSP genes. TNNI3 is the third most important disease
gene in this cohort and complete loss of myocardial TNNI3 was
associated with severe CMP and a compensatory increase in
TNNI1.
Our study serves to assess the impact of genetic testing
for counseling and management of pediatric primary CMP
patients, and it shows wide genetic heterogeneity, depending on
the stringency of phenotypes included in the cohort.2 The
strength of this pediatric study is that it included only patients
with primary CMP.
4.1 | Spectrum of genetic variants in pediatric
primary CMP
In the entire cohort, we mainly identified patients with DCM and
HCM, which is consistent with the established incidence of pediatric
CMP.5 Less frequently, we detected patients with LVNC and RCM.
F IGURE 3 Families with CMP and mutation
of TNNI3. A-F, Pedigrees of all families with rare
genetic TNNI3 variants. Open symbols depict
unaffected individuals and filled symbols affected
family members. The phenotype is indicated for
each pedigree. The TNNI3 genotype is presented
for each pedigree, with the mutated allele
marked as mut and the reference allele as wt.
Individuals without genotype were not available
for genetic testing. CMP, cardiomyopathy
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Over all CMP subtypes, genetic variants were most frequently
detected in sarcomeric genes (MYH7, MYBPC3, TNNI3) followed by
desmosomal (DSP) and z-disc genes (LDB3, MYPN).
4.1.1 | Hypertrophic cardiomyopathy
Shared genetic causes for childhood-onset and adult CMP were
first shown for HCM; in the study by Morita et al, mutations
occurred predominantly (in >75% of the children) in MYH7 and
MYBPC3.21
4.1.2 | Dilated cardiomyopathy
The spectrum of contributing genes differs among the age groups,
most prominently, when comparing the infant group with the pediatric
and adult groups.22
4.1.3 | Restrictive cardiomyopathy
A substantial proportion of pediatric RCM is caused by mutation of
sarcomere genes.23 In adults, genetic analysis of RCM is limited to
individual consanguineous families and case reports.24
F IGURE 4 Localization of TNNI3 variants and protein as well as mRNA expression. A, Structure of the TNNI3 protein with functional domains
and interaction sites. B, Genomic structure of the TNNI3 gene with localization of the detected genetic variants. C, Protein expression analysis of
heart biopsies from two patients with homozygous TNNI3 variants and controls. D, Quantification of protein levels occurred relative to HSP70
expression. E, Transcript levels of target genes were determined with quantitative polymerase chain reaction and normalized to glyceraldehyde-3-
phosphate dehydrogenase. Statistical analysis was performed with Student's t test, *P < .05 [Colour figure can be viewed at
wileyonlinelibrary.com]
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4.1.4 | Left ventricular non-compaction
Targeted NGS approaches revealed a wide spectrum of genetic varia-
tions and a high incidence of pathogenic variants in pediatric LVNC
patients, mostly sarcomere gene variants.25,26
In adult cohorts, sarcomeric genes are the major disease genes for
HCM (>70%),27 DCM (14%, 35%, or 37%),22,28,29 and LVNC (26% or
29%).30,31 In all CMP subgroups, patients carried most frequently VOI
in sarcomere genes suggesting them as major contributor in pediatric
CMP as previously shown in meta-analyses for adult-onset CMP.32,33
A detailed genotype-phenotype correlation was not intended in this
study of index-patients due to the composition and small size of the
subgroups per CMP. The cohort is phenotypically heterogeneous
which means that the five different CMPs under investigation have
different clinical characteristics and severity cannot be accounted for
by age of onset.
4.1.5 | Specific disease genes
MYH7 variants were most frequently associated with HCM, DCM,
and LVNC in our cohort. Onset of disease in 12 individuals with
MYH7 variants ranges from infancy to adolescence. In the literature,
6/9 variants previously reported were found in adults as well as in
children (Table S7). This suggests that MYH7 variants found in chil-
dren are not specific to individuals of a certain age group. Other, yet
unknown genetic or exogenous factors contribute to the age of onset
of disease. Seven MYH7 missense variants were classified as patho-
genic or probably pathogenic. All of these seven missense variants
localize within the HCM cluster region MYH7_167-931 supporting
their pathogenic character.15 Moreover, the high detection rate of
already known missense variants (only three novel MYH7 variants out
of 12) solicits reliable MYH7 disease variant identification as well as
classification.14,15 Altogether, pathogenic assessment of MYH7 vari-
ants is highly specific due to the availability of comprehensive genetic
and functional data.
In this study, we excluded TTN missense variants, due to their cur-
rently uncertain interpretation. Nevertheless, we identified four het-
erozygous TTN variants inducing premature stop of translation
(truncating variants) or potentially affecting splicing. One DCM and
two RCM patients carrying truncation TTN variants underwent HTX.
This suggests a link of TTN truncation with pediatric RCM, potentially
in combination with a more complex genetic alteration, and a critical
importance of both TTN alleles for postnatal development.24 In line
with our observations, other studies showed that in children with
DCM, the frequency of truncating TTN variants is much lower com-
pared to adults.22,34
4.1.6 | Segregation analysis
In 77% of families, we tested the variant inheritance and clinical status
in first degree members. This approach allowed us to identify seven
de novo variants (10%). This is a lower ratio of de novo variants than
previously reported.2 Vasilescu et al reported 46% de novo variants in
a cohort of infant childhood-onset CMP (median age of diagnosis of
0.33 years) and 33% of individuals in this cohort presented with a sys-
temic disorder. The interpretation of de novo variants has recently
been challenged. Numerous de novo variants associated with cardiac
disease were observed as standing variation in ExAC, thus these vari-
ants are less probably monogenic causes or major risk contributors for
cardiac disease.35
4.2 | Defective troponin I switch due to homozygous
TNNI3 mutation
This study identified two patients with either DCM (1-II:1, p.
Arg69Alafs*) or LVNC (2-II:3, c.24+2T>A) carrying homozygous
TNNI3 loss-of-function variants. It is known that heterozygous TNNI3
variants cause DCM, HCM, and RCM; however, homozygous muta-
tion of TNNI3 is a rare event,18 and to our knowledge so far, three
homozygous TNNI3 cases have been described: the missense variant
p.Ala2Val (DCM), the synonymous variant c.G150A (p.Lys50Lys) caus-
ing aberrant splicing of TNNI3 mRNA (DCM), and a genomic deletion
comprising the TNNI3 exon 8 as well as the entire TNNT2 gene
(DCM).36-38 Here, we showed absence of the TNNI3 protein in heart
tissue of patients with homozygous TNNI3 mutation. Moreover, we
suggest impaired TNNI isoform switching in the postnatal heart indi-
cated by increased TNNI1 (fetal isoform) protein and mRNA levels in
both patients. The switch from fetal TNNI1 to adult TNNI3 monitors
cardiomyocyte maturation in mammalian heart tissue and in human-
induced pluripotent stem cell-derived cardiomyocytes.39,40 More
importantly, TNNI switching critically determines Ca2+ sensitivity,
resistance to hypoxia/acidosis, and responsiveness to adrenergic stim-
ulation of the contractile system.41 Thus, defective TNNI1 to TNNI3
switching upon CMP associated TNNI3 mutation may prevent ade-
quate adaptation to postnatal heart physiology.
4.3 | Pediatric CMP: Implications for genetic testing?
It is a matter of ongoing debate whether whole genome sequencing
(WGS) or whole exome sequencing (WES) in CMP would be necessary
to provide more insight into the genetic disease mechanisms.42 The
incremental yield of clinically actionable variants by WGS is limited by
a paucity of genetic and functional evidence.43 In a study by Herkert
et al, combining copy number variant analysis with stepwise trio-
based WES yielded a diagnosis in more than 50% of pediatric DCM
patients.44 They identified patients with familial and non-familial
DCM or a mixed cardiac phenotype with age at onset of CMP
<18 years. These included patients with extracardiac features or pos-
sible myocarditis. Other recent studies lead to the identification of
pathogenic variants in 26% to 39% of pediatric patients.1,2 Our study
suggests genetic testing for sarcomere gene variants in severely
affected children as early as possible to support clinical decision mak-
ing. Altogether, these studies support the use of genetic testing in
clinical practice by NGS, to improve risk stratification for clinically
affected patients in selected CMP, such as pediatric CMP.45
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In summary, with an NGS panel-based approach, we identified the
genetic cause in 38% of pediatric patients with primary CMP. Most
frequently, we detected pathogenic or probably pathogenic missense
variants in sarcomere genes such as MYH7, MYBPC3, and TNNI3.
Homozygous deactivation of TNNI3 leads to severe CMP in pediatric
patients and compensatory expression of TNNI1. We propose that
this study advances the general genetic understanding of pediatric pri-
mary CMP and highlights certain genetic defects with severe clinical
courses.
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